Logo image of LYRA

LYRA THERAPEUTICS INC (LYRA) Stock Fundamental Analysis

NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD

15.98  -2.44 (-13.25%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LYRA. LYRA was compared to 195 industry peers in the Pharmaceuticals industry. LYRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, LYRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LYRA has reported negative net income.
LYRA had a negative operating cash flow in the past year.
In the past 5 years LYRA always reported negative net income.
In the past 5 years LYRA always reported negative operating cash flow.
LYRA Yearly Net Income VS EBIT VS OCF VS FCFLYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

LYRA has a Return On Assets of -141.22%. This is amonst the worse of the industry: LYRA underperforms 83.08% of its industry peers.
Looking at the Return On Equity, with a value of -2053.98%, LYRA is doing worse than 83.08% of the companies in the same industry.
Industry RankSector Rank
ROA -141.22%
ROE -2053.98%
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
LYRA Yearly ROA, ROE, ROICLYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

LYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYRA Yearly Profit, Operating, Gross MarginsLYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LYRA has been increased compared to 1 year ago.
Compared to 5 years ago, LYRA has more shares outstanding
LYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LYRA Yearly Shares OutstandingLYRA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
LYRA Yearly Total Debt VS Total AssetsLYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of 1.54, we must say that LYRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.54, LYRA is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
LYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.54
ROIC/WACCN/A
WACC10.15%
LYRA Yearly LT Debt VS Equity VS FCFLYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

LYRA has a Current Ratio of 2.96. This indicates that LYRA is financially healthy and has no problem in meeting its short term obligations.
LYRA's Current ratio of 2.96 is in line compared to the rest of the industry. LYRA outperforms 52.31% of its industry peers.
A Quick Ratio of 2.96 indicates that LYRA has no problem at all paying its short term obligations.
LYRA has a Quick ratio of 2.96. This is comparable to the rest of the industry: LYRA outperforms 56.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
LYRA Yearly Current Assets VS Current LiabilitesLYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

LYRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.45%.
LYRA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.38%.
Measured over the past years, LYRA shows a very strong growth in Revenue. The Revenue has been growing by 74.24% on average per year.
EPS 1Y (TTM)-3.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.71%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-65.6%

3.2 Future

The Earnings Per Share is expected to grow by 14.89% on average over the next years. This is quite good.
Based on estimates for the next years, LYRA will show a very strong growth in Revenue. The Revenue will grow by 134.91% on average per year.
EPS Next Y59.88%
EPS Next 2Y23.57%
EPS Next 3Y14.85%
EPS Next 5Y14.89%
Revenue Next Year-24.65%
Revenue Next 2Y223.19%
Revenue Next 3Y157.48%
Revenue Next 5Y134.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYRA Yearly Revenue VS EstimatesLYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
LYRA Yearly EPS VS EstimatesLYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LYRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYRA Price Earnings VS Forward Price EarningsLYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYRA Per share dataLYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

LYRA's earnings are expected to grow with 14.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.57%
EPS Next 3Y14.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LYRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYRA THERAPEUTICS INC

NASDAQ:LYRA (6/10/2025, 2:22:29 PM)

15.98

-2.44 (-13.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners31.66%
Inst Owner Change-5.41%
Ins Owners3.08%
Ins Owner Change48.15%
Market Cap1.06B
Analysts48.89
Price TargetN/A
Short Float %N/A
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.4%
Min EPS beat(2)-30.72%
Max EPS beat(2)13.92%
EPS beat(4)2
Avg EPS beat(4)-28.85%
Min EPS beat(4)-121.19%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)-9.02%
EPS beat(12)7
Avg EPS beat(12)-6.89%
EPS beat(16)8
Avg EPS beat(16)-7.79%
Revenue beat(2)0
Avg Revenue beat(2)-14.35%
Min Revenue beat(2)-25.25%
Max Revenue beat(2)-3.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.34%
Min Revenue beat(4)-40.26%
Max Revenue beat(4)67.6%
Revenue beat(8)4
Avg Revenue beat(8)28.96%
Revenue beat(12)6
Avg Revenue beat(12)32.2%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4542.86%
EPS NQ rev (3m)-6090.48%
EPS NY rev (1m)-3833.57%
EPS NY rev (3m)-3961.37%
Revenue NQ rev (1m)21.76%
Revenue NQ rev (3m)180.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 893.67
P/FCF N/A
P/OCF N/A
P/B 273.5
P/tB 273.5
EV/EBITDA N/A
EPS(TTM)-60
EYN/A
EPS(NY)-33.83
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.02
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -141.22%
ROE -2053.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z 1.54
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)295.99%
Cap/Depr(5y)601.39%
Cap/Sales(3y)77.13%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.71%
EPS Next Y59.88%
EPS Next 2Y23.57%
EPS Next 3Y14.85%
EPS Next 5Y14.89%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-65.6%
Revenue Next Year-24.65%
Revenue Next 2Y223.19%
Revenue Next 3Y157.48%
Revenue Next 5Y134.91%
EBIT growth 1Y37.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.16%
OCF growth 3YN/A
OCF growth 5YN/A